FindTrial
Sign In

Lanabecestat

DRUG10 trials

Sponsors

AstraZeneca, Eli Lilly and Company

Conditions

Alzheimer's DiseaseAlzheimer´s DiseaseHealthyRenal Insufficiency

Phase 1

A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants
CompletedNCT02406261
AstraZenecaHealthy
Start: 2015-04-30End: 2015-08-31Updated: 2019-11-04
A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants
CompletedNCT02540668
AstraZenecaHealthy
Start: 2015-09-30End: 2016-01-31Updated: 2019-11-04
A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants
CompletedNCT02568397
AstraZenecaHealthy
Start: 2015-10-31End: 2016-01-31Updated: 2019-11-01
A Study of Lanabecestat (LY3314814) in Healthy Participants
CompletedNCT02663128
AstraZenecaHealthy
Start: 2016-01-31End: 2016-03-31Updated: 2019-11-01
A Study of Lanabecestat (LY3314814) in Healthy Participants When Taken With Rosuvastatin
CompletedNCT03019549
AstraZenecaHealthy
Start: 2017-01-12End: 2017-05-22Updated: 2019-11-01
A Study of Lanabecestat in Healthy Female Participants Taking Oral Contraceptive
WithdrawnNCT03506399
Eli Lilly and CompanyHealthy
Start: 2018-06-30End: 2018-10-31Updated: 2018-06-28
A Study of Lanabecestat in Participants With Severe Kidney Impairment Compared to Healthy Participants
WithdrawnNCT03545087
Eli Lilly and CompanyRenal Insufficiency
Start: 2018-06-30End: 2019-01-31Updated: 2018-06-28

Phase 2

An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
TerminatedNCT02245737
AstraZenecaAlzheimer´s Disease
Start: 2014-09-30End: 2018-10-04Updated: 2019-12-03

Phase 3

A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
TerminatedNCT02783573
AstraZenecaAlzheimer's Disease
Start: 2016-07-01End: 2018-09-28Updated: 2019-12-03
A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia
TerminatedNCT02972658
AstraZenecaAlzheimer's Disease
Start: 2017-03-15End: 2018-10-02Updated: 2019-12-03

Related Papers

Turning failure into success: how artificial intelligence can help personalize therapies and re-use patient data
Purinergic Signalling2026-05-29
The Alzheimer's Disease Cooperative Study - Activities of Daily Living dependence score: revision and validation of an algorithm evaluating patient dependence across the spectrum of AD severity.
2025-07-01
Bayesian network analysis of BIN1 risk allele and other risk factors and biomarkers of Alzheimer’s disease
Alzheimer s & Dementia2023-12-011 citations
To Assess Mediation Effects of BIN1 Risk Variant rs6733839 and APOE4 on Alzheimer’s disease Pathology
Alzheimer s & Dementia2023-12-011 citations
Data‐Driven Methods Highlight Early Signals of Tau in Patients Lacking Global Uptake: Facilitating Enrollment in Clinical Trials
Alzheimer s & Dementia2022-12-01
Health care utilization patterns in early symptomatic AD prior to enrollment into Phase 2/3 clinical trial AMARANTH
Alzheimer s & Dementia2021-12-01
Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease
JAMA Neurology2021-02-1553 citations
Reasons for study exclusion by sex in lanabecestat studies AMARANTH and DAYBREAK‐ALZ
Alzheimer s & Dementia2020-12-01
Longitudinal flortaucipir accumulation is spatially distinct across baseline tau burden stages: Summary from three phase 2/3 interventional trials in Alzheimer’s disease
Alzheimer s & Dementia2020-12-01
Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study.
2020-05-1480 citations
Clinically Negligible Pharmacokinetic and Pharmacodynamic Interactions Between Lanabecestat and Dabigatran Etexilate, a Prototypical P‐gp Substrate
The Journal of Clinical Pharmacology2019-12-183 citations
Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease
JAMA Neurology2019-11-25189 citations
FTS3‐01‐02: SUBGROUP POPULATIONS IN AMARANTH, A RANDOMIZED PHASE 2/3 STUDY IN EARLY ALZHEIMER'S DISEASE WITH LANABECESTAT
Alzheimer s & Dementia2019-07-011 citations
FTS3‐01‐03: PERFORMANCE ON EXPLORATORY EFFICACY VARIABLES IN AMARANTH, A RANDOMIZED PHASE 2/3 STUDY IN EARLY ALZHEIMER'S DISEASE WITH LANABECESTAT
Alzheimer s & Dementia2019-07-011 citations
Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study
Alzheimer s Research & Therapy2018-08-22106 citations
DT‐01‐04: LANABECESTAT: BASELINE CHARACTERISTICS OF PARTICIPANTS RANDOMIZED IN THE PHASE 2/3 AMARANTH STUDY
Alzheimer s & Dementia2018-07-011 citations
P1‐039: LANABECESTAT DOES NOT AFFECT PHARMACOKINETICS OF THE BCRP SUBSTRATE ROSUVASTATIN
Alzheimer s & Dementia2018-07-01
P4‐210: LANABECESTAT: SCREENING PERFORMANCE FROM THE AMARANTH STUDY
Alzheimer s & Dementia2018-07-01
Clinical Bioavailability of the Novel BACE1 Inhibitor Lanabecestat (AZD3293): Assessment of Tablet Formulations Versus an Oral Solution and the Impact of Gastric pH on Pharmacokinetics
Clinical Pharmacology in Drug Development2018-01-1016 citations
[P4–207]: A PRESCREENING STUDY IN SPAIN TO IDENTIFY INDIVIDUALS WHO MIGHT BE SUITABLE FOR PARTICIPATION IN CLINICAL STUDIES IN EARLY ALZHEIMER's DISEASE UTILIZING REFERRALS FROM GENERAL PRACTITIONER NETWORKS
Alzheimer s & Dementia2017-07-01

3 more papers not shown